Hong Kong boosts medical technology spending
This article was originally published in Clinica
The Hong Kong government has announced plans to expand its stock of medical devices. The territory's first budget since its handover from the UK to China has increased total healthcare spending by 5.6% to HK$31.5 billion ($4.1 billion), giving the Hospital Authority scope to go shopping.
You may also be interested in...
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.